Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Phase 3 Completed 63 enrolled Ipsen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatostatin analogues.

Timeline

Start: 2000-09
Primary completion: 2002-07-15
Completion: 2002-07-15

Publications

Results Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B; Lanreotide Acromegaly Study Group. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008 Aug;69(2):299-305. doi: 10.1111/j.1365-2265.2008.03208.x. Epub 2008 Jan 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanreotide	Other / unclassified	60 mg	Other
Subject	Lanreotide	Other / unclassified	90 mg	Other
Subject	Lanreotide	Other / unclassified	120 mg	Other

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Summary

Timeline

Publications

Drugs

Indications